Nigeria's proposed drug ban offers no safety net, says local newspaper

28 April 2010

There is the gloomy predicament confronting Nigeria today as the local pharmaceutical drug manufacturing industry is unable to rise up to the demands of the drug manufacture/distribution/supply needs of the people, reports the local Vanguard newspaper.

That a lot remains to be desired as far as the local pharmaceutical drug manufacturing industry is concerned is not in doubt. Neither is there controversy that urgent and drastic measures are desirable in bringing about appreciable measure of order into the apparent reign of disorder in which the local drug manufacturing industry is currently enmeshed.

This scenario persists, no thanks to the dwindling fortunes of a troubled health sector that is perpetually giving more cause for jeer than for cheer. Things appear to have fallen apart as the center no longer holds for the local pharmaceutical drug manufacturing industry which remains wanting in the areas of R&D, capacity utilization, near-total dependence on importation of raw materials, faulty regulatory environment, a chaotic drug distribution process and proliferation of spurious, fake, substandard and adulterated drug products, to mention just a few.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics